Dr. Rose on the Results of the BEAVER Trial in Non-V600E BRAF-Mutant Advanced Solid Tumors

April Rose, MD, discusses the efficacy results of the ongoing phase 2 BEAVER trial in non-V600E BRAF-mutant advanced solid tumors.

April Rose, MD, assistant professor of oncology, Gerald Bronfman Department of Oncology, McGill University, discusses the efficacy results of the ongoing phase 2 BEAVER trial (NCT03839342) in non-V600E BRAF-mutant advanced solid tumors.

The BEAVER trial is an open-label, single-center study examining the use of binimetinib (Mektovi) plus encorafenib (Braftovi) in adult patients with advanced and/or metastatic solid tumors that harbor non-V600E BRAF mutations. Patients were a median age of 61 years and the majority had received at least 2 systemic therapies, Rose explains. Patients with a variety of different cancer types were enrolled on the study, including melanoma, colorectal, pancreatic, gallbladder, ampullary, breast, non–small cell lung, and uterine cancers, Rose adds.

Regarding efficacy, 2 of 11 patients responded with the combination of binimetinib and encorafenib, Rose continues. Additionally, 2 patients achieved stable disease, whereas all remaining patients developed progressive disease. This translated to an overall response rate of 18%, Rose concludes.

Related Videos
View All
Related Content